Zumutor is happy to announce that it received a notice of allowance from USPTO on its flagship product : ZM008
ZM008 is a novel monoclonal antibody: designed and developed by scientists at Zumutor Biologics.
This Ab will have far reaching impact on patient outcomes in solid cancers especially those with limited standard therapeutic options.
Clinical trials will commence soon in the US.